logo
Plus   Neg
Share
Email
Comment

Merck Gets FDA Approval Of Prevymis For Prevention Of CMV Infection

Merck & Co., Inc. (MRK), known as MSD outside the United States and Canada, said that the U.S. Food and Drug Administration has approved Prevymis or letermovir once-daily tablets for oral use and injection for intravenous infusion.

Prevymis is indicated for prophylaxis or prevention of cytomegalovirus or CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).

CMV is a common and potentially serious viral infection in allogeneic HSCT recipients. CMV-seropositive patients who undergo an HSCT are at high risk for CMV reactivation. Any level of CMV infection is associated with increased mortality in HSCT patients.

In the pivotal Phase 3 clinical trial supporting approval, significantly fewer patients in the Prevymis group, or 38 percent, compared to the placebo group or 61 percent, developed clinically significant CMV infection, discontinued treatment or had missing data through Week 24 post-HSCT, the primary efficacy endpoint.

Prevymis is expected to be available in December. The list price per day for Prevymis tablets is $195.00 and for Prevymis injection is $270.00. Wholesaler acquisition costs do not include discounts that may be paid on the product.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cannae Holdings, Inc. said Wednesday that its portfolio company, Ceridian HCM Holding Inc., has confidentially filed for an initial public offering. Ceridian HCM, a provider of human resources software and services, filed a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission relating to the proposed IPO of its common stock. Goldman Sachs Group Inc. on Wednesday reported a loss for the fourth quarter, reflecting lower trading revenue in fixed income, currencies and commodities as well as a charge related to the recent U.S. tax reform. However, both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Bank of America Corp. (BAC) reported a profit for the fourth-quarter of 2017 that declined about 50 percent from last year, hurt by a charge of $2.9 billion or $0.27 per share, related to the Tax Cuts and Jobs Act.
comments powered by Disqus
Follow RTT